Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

Christos I Sinapis1,*
John G Routsi2,*
Angelos I Sinapis1,*
Dimitrios I Sinapis1,*
George D Agrogiannis3
Alkistis Pantopoulou1
Stamatis E Theocharisis4
Stefanos Baltatzis5
Efstratios Patsouris3
Despoina Perrea1

1Laboratory for Experimental Surgery and Surgical Research ‘N.S.Christeas’,
Laboratory of Pathophysiology,
Laboratory of Pathology, Laboratory of Forensic Medicine and Toxicology,
Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
*Contributed equally to the study

Purpose: To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits.

Methods: The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous.

Results: Maximum vitreous (406.25 µg/mL) and aqueous humor (5.83 µg/mL) concentrations of bevacizumab in the right eye were measured at day 1. Serum bevacizumab concentration peaked at day 8 (0.413 µg/mL) and declined to 0.032 µg/mL at 4 weeks. Half-life values in right vitreous, right aqueous humor, and serum were 6.61, 6.51, and 5.87 days, respectively. Concentration of bevacizumab in the vitreous of the noninjected eye peaked at day 8 (0.335 ng/mL) and declined to 0.218 ng/mL at 4 weeks. In the aqueous humor of the noninjected eye, maximum concentration of bevacizumab was achieved at day 8 (1.6125 ng/mL) and declined to 0.11 ng/mL at 4 weeks.

Conclusion: The vitreous half-life of 1.25 mg/0.05 mL intravitreal bevacizumab was 6.61 days in this rabbit model. Maximum concentrations of bevacizumab were reached at day 1 in both vitreous and aqueous humor of the right eye and at day 8 in the serum. Very low concentrations of bevacizumab were measured in the fellow noninjected eye.

Keywords: bevacizumab, pharmacokinetics, rabbits, intravitreal

Introduction

Bevacizumab (Avastin®, Genentech, South San Francisco, CA) is a humanized monoclonal antibody that inhibits human vascular endothelial growth factor (VEGF). VEGF is an endothelial cell-specific mitogen required for pathological angiogenesis observed in tumor growth and metastatic spread. Therefore, bevacizumab has been approved by the US Food and Drug Administration as an adjunct treatment for metastatic colorectal cancer.1 Bevacizumab is composed of 214 amino acids with a molecular mass of 149 kDa. Although some studies2 suggest that molecules exceeding 100 kDa cannot cross the retinal layers into the subretinal space, a number of other studies3,4 have demonstrated that bevacizumab can efficiently diffuse through the retinal layers into the choroidal space where it can inhibit neovascularization. In this regard, intravitreal injections of bevacizumab for off-label use have been shown to be beneficial in eyes with macular edema secondary to neovascular age-related macular degeneration (AMD),5,6 diabetic retinopathy,7–9 and central or branch retinal vein occlusion.10–12

The pharmacokinetics and distribution of bevacizumab after intravitreal injection of 1.25 mg/0.05 mL in rabbits have been studied.13,14 Interestingly, in these studies, very low concentrations of bevacizumab were detected in the fellow noninjected eye,
approaching the detection limit of the methods used. In our study, we aimed to measure the concentrations of bevacizumab in both the injected and noninjected eye with more sensitive methods. It is important to know the exact pharmacokinetic profile of bevacizumab to optimize doses, assess its safety profile, and achieve the best therapeutic results not only in the injected but also in the noninjected eye.

**Methods**

Approval was obtained from the Ethics Committee of the National and Kapodistrian University of Athens and the Veterinary Address of Prefecture of Athens. The procedures adhered to the guidelines of the Association for Research in Vision and Ophthalmology for animal use in ophthalmic and vision research and were in accordance with the standards set down in the Guide for the Care and Use of Laboratory Animals. Twenty-four male New Zealand rabbits with a mean weight of 2.8975 kg (±0.2028 kg) were anesthetized with 20 mg/kg of intramuscular ketamine hydrochloride and 3 mg/kg of intramuscular xylazine hydrochloride. Ophthalmic drops of 1% alcaine hydrochloride were placed on the conjunctiva of 20 right eyes and then povidone iodine 5% was instilled in these eyes. These right eyes were injected intravitreally 2 mm behind the surgical limbus in the superotemporal quadrant with bevacizumab 1.25 mg/0.05 mL using a 30-gauge needle. The 20 left eyes received no intravitreal injections and acted as controls. Eyes were monitored closely daily for any signs of adverse effects. Four rabbits received no intravitreal injections in the right eye and acted as controls to determine the background levels in the detection of bevacizumab.

Four of the rabbits that received intravitreal injections of bevacizumab were sacrificed at each of the following days: 1, 3, 8, 15, and 29. Rabbits were first anesthetized with 20 mg/kg of intramuscular ketamine hydrochloride and 3 mg/kg of intramuscular xylazine hydrochloride and then a sample of arterial blood was drawn from the central artery of their ears just before the euthanasia. Rabbits were then sacrificed with pentobarbital overdose (1.2 mL/kg). Serum was obtained by allowing the blood sample to clot at room temperature for 1 hour followed by centrifugation. Serum was then frozen at −80°C until tested. The vitreous was taken with a 2.5 mL syringe while aqueous humor was withdrawn into an insulin syringe. All samples were immediately frozen at −80°C until tested. The four rabbits that acted as control animals were sacrificed and samples were obtained as mentioned above at day 0.

**Bevacizumab assay**

Bevacizumab concentrations were measured using enzyme-linked immunosorbent assay (ELISA). Two ELISA methods were used, one of low sensitivity (LS ELISA, linear range: 5 ng/mL to 0.1 µg/mL, Figure 1A) and one of high sensitivity (HS ELISA, linear range: 10 pg/mL to 5 ng/mL, Figure 1B). ELISA plates (Costar high binding) were coated with 100 µL/well of rec-hVEGF (R&D Systems, Minneapolis, MN) at a concentration of 0.2 µg/mL in carbonate-bicarbonate buffer (pH = 9.6). After washing with PBS (200 µL/well), the plates were blocked with 200 µL/well of bovine albumin 2% in PBS (BB: blocking buffer). Afterwards, the plates were washed and the samples were added (100 µL/well) in various dilutions ranging from 1:10,000 (vitreous/right eye day 1) to 1:1 (vitreous/left eye day 29) and incubated for 2 hours at room temperature (RT). The plates were then washed again and for i) LS ELISA: 100 µL/well of anti-human Fab specific antibody conjugated to horse radish peroxidase (HRP) (Sigma-Aldrich, St Louis, MO) (1:1200 in BB) was added to the wells. After washing, 100 µL of ABTS [2, 2′-azino-bis (3-ethylbenzthiazoline-6-sulfonicacid)] substrate was added to the wells and the color development was measured at 405 nm, ii) HS ELISA: 100 µL/well of anti-human Fab specific antibody conjugated to alkaline phosphatase (AP) (Jackson Immuno research, West Grove, PA) (1:1200 in BB) was added to the wells. Subsequently, the plates were washed four times with PBS and the Invitrogen’s ELISA amplification system was used to

**Figure 1** Development of specific assays for the quantification of bevacizumab: A) low sensitivity ELISA with linear range 5 to 100 ng/mL; B) high sensitivity ELISA with linear range 10 to 5000 pg/mL. **Abbreviation:** OD, optical density.
enhance the detection of bevacizumab. Briefly, the plates were incubated with 50 µL/well of substrate (reduced NADPH) for 20 minutes followed by the addition of 50 µL/well of amplifier (alcohol dehydrogenase and diaphorase). The color was quantified at 490 nm.

The detection limit of the designed assay was evaluated using decreasing concentrations of bevacizumab. The detection limit was found to be 0.01 ng/mL (with the high-sensitivity assay). Intra- and inter-assay variations were calculated using the formula:

\[
\% CV = \frac{SD \times 100}{X}
\]

where \( CV \) = coefficient of variation, \( SD \) = standard deviation and \( X \) = mean.

Each dilution of bevacizumab was run eight times to calculate the coefficient of variation. Mean intra-assay and inter-assay \( CV \) were found to be 3.96% and 6.75% for the low-sensitivity assay and 4.4% and 8.19% for the high-sensitivity assay, respectively.

**ELISA assay for detection of anti-bevacizumab antibodies (rabbit anti-Idiotype antibodies)**

We additionally performed an ELISA assay for detection of anti-bevacizumab antibodies in order to quantify their effect on bevacizumab concentration. According to this method, ELISA plates (Costar high binding) were coated with 100 µL/well of bevacizumab at a concentration of 0.4 µg/mL in carbonate-bicarbonate buffer (pH = 9.6). After washing with PBS (200 µL/well), the plates were blocked with 200 µL/well of bovine albumin 2% in PBS (BB: blocking buffer).

Subsequently, the serum samples were added (100 µL/well) in 1:5 dilution and incubated for 2 hours at RT. The plates were then washed again and 100 µL/well of anti-rabbit Fc specific antibody conjugated to AP (1:1200 in BB) was added to the wells. Afterwards, the plates were washed with PBS (200 µL/well) and the Invitrogen ELISA amplification system was used according to the procedure described above. Finally, the color was quantified at 490 nm.

**Pharmacokinetic methods**

Bevacizumab vitreous humor, aqueous humor, and serum concentration–time data were each fit by standard noncompartmental analysis to determine half-life (\( t_{1/2} \)), area under the curve (\( AUC_{(0\rightarrow\infty)} \)) and bevacizumab vitreous clearance using WinNonlin Pro (v2.1; Pharsight, Mountain View, CA). The terminal elimination rate constant was determined by least-squares regression of the ln (serum concentration)–time data for the last four time points.

**Results**

Data were obtained from the 48 eyes of 24 rabbits. There were no signs of ocular inflammation or other adverse events. The change in concentration over time for bevacizumab in the vitreous and aqueous humor of injected eye and in serum after intravitreal injection is illustrated in Figure 2. A peak concentration of 406.25 µg/mL was achieved in the vitreous 1 day after intravitreal injection of 1.25 mg/0.05 mL bevacizumab. Half-life of bevacizumab in the right vitreous was 6.61 days (Table 1). A concentration of 5.17 µg/mL was maintained in the vitreous 29 days after injection. Bevacizumab concentrations in the aqueous humor of the injected eye reached a peak concentration of 5.835 µg/mL 1 day after drug administration as well. A concentration of 0.225 µg/mL was maintained in aqueous humor 29 days after injection. In serum, a maximum concentration of 0.413 µg/mL was achieved 8 days after drug injection and the concentration fell to 0.032 µg/mL 29 days after injection.

**Table 1** Analysis of distribution of bevacizumab in the aqueous, vitreous, and serum after intravitreal injection of 1.25 mg/0.05 mL bevacizumab in the right eye.

<table>
<thead>
<tr>
<th>Compartiment</th>
<th>( t_{1/2} ) (days)</th>
<th>( T_{max} ) (days)</th>
<th>( C_{max} ) (ng/mL)</th>
<th>( % ) of vitreous</th>
<th>( C_{max} )</th>
<th>AUC(_{(0\rightarrow\infty)}) (µg/mL * day)</th>
<th>Exposure to bevacizumab as a % of vitreous exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitreous (R)</td>
<td>6.61</td>
<td>1</td>
<td>406250</td>
<td>–</td>
<td>0.34</td>
<td>0.00008</td>
<td>0.001</td>
</tr>
<tr>
<td>Aqueous (R)</td>
<td>6.51</td>
<td>1</td>
<td>5835</td>
<td>1.44</td>
<td>413</td>
<td>0.018</td>
<td>3.08</td>
</tr>
<tr>
<td>Serum</td>
<td>5.87</td>
<td>8</td>
<td>413</td>
<td>0.10</td>
<td>1.61</td>
<td>0.017</td>
<td>0.001</td>
</tr>
<tr>
<td>Aqueous (L)</td>
<td>5.56</td>
<td>8</td>
<td>0.34</td>
<td>0.0004</td>
<td>0.00008</td>
<td>0.017</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**Abbreviations:** R, right eye; L, left eye; \( T_{max} \), day when concentration of bevacizumab peaked; \( C_{max} \), maximum concentration; AUC, area under the curve.
after drug administration. Half-life of bevacizumab in the right aqueous humor and serum were 6.51 and 5.87 days, respectively (Table 1).

Very low concentrations of the drug were detected in the fellow noninjected eye. The levels of bevacizumab in the aqueous humor of the noninjected eye peaked at 8 days after intravitreal injection with a concentration of 1.61 ng/mL and declined to 0.11 ng/mL at 29 days. For the vitreous of the noninjected eye, the levels of bevacizumab ranged from 0.245 ng/mL at 1 day after injection to a maximum of 0.335 ng/mL at 8 days and then declined to 0.218 ng/mL at 29 days. Figure 3 shows the change in concentration of bevacizumab in the aqueous and vitreous humor of the fellow noninjected eye.

**Figure 2** Bevacizumab concentration in the vitreous, aqueous humor, and serum after intravitreal injection of 1.25 mg/0.05 mL of bevacizumab in rabbits. Samples were taken from the aqueous humor and vitreous of the injected right eye. Values at day 0 indicate background levels of bevacizumab detection in control animals.

**Figure 3** Bevacizumab concentration in the vitreous and the aqueous humor of the noninjected left eye after intravitreal injection of 1.25 mg/0.05 mL bevacizumab into the fellow eye. Values at day 0 indicate background levels of bevacizumab detection in control animals.
The results of high sensitivity ELISA assay for the detection of anti-bevacizumab antibodies are illustrated in Figure 4. There was a 30% increase of anti-bevacizumab antibodies at day 1, 60% at day 3, and 70% at day 8. Subsequently, the anti-bevacizumab activity of antibodies gradually decreased (to 120% of the initial levels at day 29), following the elimination of bevacizumab from blood circulation. Taking into account the absolute optical density values of the measurements of the high sensitivity ELISA, compared with the high sensitivity assay for bevacizumab, we can conclude that the concentration of anti-bevacizumab antibodies in serum is at least 200-fold lower than the bevacizumab concentration. Therefore, anti-bevacizumab antibodies cannot have an important effect on bevacizumab concentration because of their low concentration.

The cytotoxicity of the drug is currently under investigation in our laboratory. Our preliminary results show no important histological changes in all the anatomical parts that were examined by light microscopy (Figure 5). In both injected and noninjected eyes, no signs of necrosis or degeneration of the retina were noticed and the retinal thickness was unchanged. Only some specimens of the right injected eyes revealed chronic inflammatory infiltrations (indicated by arrows in Figure 5) consisting of lymphocytes, plasma cells, and rarely eosinophils. The left noninjected eyes had no histological changes as seen by light microscopy.

**Discussion**

In our study, we aimed to describe the pharmacokinetics of 1.25 mg/0.05 mL intravitreal bevacizumab in rabbits. This is the dose that is currently being used in human eyes and is widely described in the literature. The assay we used measures free bevacizumab and does not detect complexes of bevacizumab with bound VEGF. Assays which detect only the free drug are used widely in pharmacologic research and results are usually considered good representations of total drug concentration. However, an underestimation of the total bevacizumab concentration by our results cannot be excluded because of partial denaturation or proteolytic degradation of bevacizumab which may take place in samples.

Studies of pharmacokinetics of intravitreal bevacizumab in rabbits have already been published. Nevertheless, it is very important to make measurements as accurate as possible in order to know the exact pharmacokinetics of bevacizumab and optimize drug dosing and therapeutic results in both injected and noninjected eyes.

Our results show that the maximum concentration of bevacizumab in the right vitreous is measured at day 1 after injection (406 µg/mL) and then declines, but it remains at high levels 29 days after injection (5 µg/mL). Maximum concentration of bevacizumab in right aqueous was measured at day 1 as well and not at day 3 as in the Bakri et al study, in which it was much lower (5.8 µg/mL instead of 37.7 µg/mL). Maximum concentration of bevacizumab in serum is measured 8 days after intravitreal injection due to its gradual distribution from the right eye to serum (vitreousR→aqueousR→serum). On the same day (day 8), we measured the maximum concentration of bevacizumab in the left aqueous because bevacizumab is very easily and quickly distributed from serum to left aqueous (serum→aqueousL). The concentration of bevacizumab in the left vitreous reached a peak concentration at day 8 and then gradually declined, not constantly raised as in the Bakri et al study. The reduction of bevacizumab concentration in the

---

**Figure 4** Quantification of anti-bevacizumab antibodies in serum of rabbits at day 0 (before intravitreal injection of bevacizumab) and at days 1, 3, 8, 15, and 29 after injection. **Abbreviation:** OD, optical density.
as their fragments were quantified with questionable ability both native and denatured bevacizumab molecules as well antibodies with a detection limit of 0.1 ng/mL. In that case, et al used anti-rabbit IgG (Heavy molecules with a detection limit of 0.01 ng/mL. Nomoto used in order to capture and quantify 'active' bevacizumab compared with those of the Bakri et al study.13 measured considerably lower concentrations in the fellow eye of bevacizumab in the noninjected eye. This is the reason we assure the accurate detection of the very low concentrations HS assay (with detection limit at 5 pg/mL) was necessary to increase of the measurement errors. On the other hand, the dilutions in the order of 1 million-fold, required for the measurement of bevacizumab with the HS assay in the right eye, which would inevitably be accompanied by a 1 million-fold increase of the measurement errors. On the other hand, the HS assay (with detection limit at 5 pg/mL) was necessary to assure the accurate detection of the very low concentrations of bevacizumab in the noninjected eye. This is the reason we measured considerably lower concentrations in the fellow eye compared with those of the Bakri et al study.13
We also measured considerably lower concentrations in the aqueous and vitreous of the fellow noninjected eye and higher concentrations in the aqueous and vitreous of the injected eye compared with the values in the Nomoto et al study.14 In addition, we measured lower concentrations in serum and we found that the maximum concentration of bevacizumab in serum was achieved at day 8 and not at day 14, as in the Nomoto et al study.14 In our assay, hVEGF was used in order to capture and quantify 'active' bevacizumab molecules with a detection limit of 0.01 ng/mL. Nomoto et al used anti-rabbit IgG (Heavy + Light chains) to capture antibodies with a detection limit of 0.1 ng/mL. In that case, both native and denatured bevacizumab molecules as well as their fragments were quantified with questionable ability to recognize hVEGF. Moreover, we obtained samples more frequently during the first month (days 1, 3, 8, 15, and 29) and thus we demonstrated a more detailed pharmacokinetic profile of bevacizumab during the first month compared with the Nomoto et al study. Finally, our results depict the variations between animals and the development of anti-bevacizumab antibodies.

The variability of results between animals was very low for the right eye but considerably higher for the left eye (see error bars in Figures 2 and 3). The maximum variability was observed at day 15 for one of the rabbits (rabbit with identification number R13), which had considerably higher concentration of bevacizumab in the left eye than the other three rabbits on the same day (0.63 ng/mL in the left vitreous and 0.8 ng/mL in the left aqueous, while the other three rabbits had an average of 0.19 ng/mL and 0.25 ng/mL in the left vitreous and left aqueous on the same day, respectively). These very high concentrations of bevacizumab in rabbit R13 may have been caused by a higher distribution rate of drug from the right vitreous to serum and then to the left aqueous and vitreous, most probably due to inflammation, infection, or traumatic damage of vessels in the injection area.

As we have already mentioned, very low concentrations of bevacizumab were detected in the fellow noninjected eye. It is very important to know if these concentrations are able to achieve therapeutic results in this eye. Wang et al17 found that bevacizumab displayed a dose-dependent inhibition in an in vitro endothelial cell proliferation assay, with an estimated median inhibition concentration of 22 ng/mL. In our study, the maximum concentration of bevacizumab in the vitreous of the noninjected eye was much lower (0.335 ng/mL). Our findings suggest that intravitreal injection of 1.25 mg/0.05 mL bevacizumab in one eye cannot achieve therapeutic concentrations in the fellow noninjected eye, even though Avery et al10 reported that some patients with bilateral proliferative diabetic retinopathy had regression of neovascularization in both eyes when injected with intravitreal bevacizumab in only one eye.

Rabbits have been widely used in order to study intravitreal pharmacokinetics of drugs.18–20 There are some differences between humans and rabbits which may affect the study of the drug's pharmacokinetics. The most important are that humans have a larger vitreous cavity (4.5 mL instead of 1.5 mL in rabbits), a larger serum compartment, and a more vascular retina. Krohne et al,21 in a study of pharmacokinetics of intravitreal bevacizumab in humans, found that after a single intravitreal injection of 1.5 mg bevacizumab,
the concentration of the drug in the aqueous humor peaked on the first day after injection (33.3 µg/mL) and dropped to less than 5 µg/mL at day 28. These concentrations are much higher than those in our study (5.8 and 0.2 µg/mL, respectively). Zhu et al measured vitreous levels of bevacizumab after intravitreal injection of 1.25 mg of bevacizumab and found that maximum concentration was achieved at day 2 after injection instead of day 1 in our study. Furthermore, the maximum concentration of bevacizumab was 165 µg/mL instead of 406 µg/mL in our study.

In our study, we used nonvitrectomized eyes. In vitrectomized eyes, clearance of the drug may be markedly increased. After intravitreal injection of triamcinolone acetonide in rabbits, the half-life in the aqueous humor was reported to be 2.89 days in nonvitrectomized eyes and 1.57 days in vitrectomized eyes. In humans, Beer et al reported that the half-life of the same drug in the aqueous humor after intravitreal injection of triamcinolone acetonide was 18.6 days in nonvitrectomized eyes compared with 3.2 days in vitrectomized eyes. Similar effects should be expected for bevacizumab in vitrectomized eyes and may result in a lack of clinical effect of bevacizumab, as reported by Yanyali et al in vitrectomized human eyes with diabetic macular edema.

Besides bevacizumab, its derivative drug ranibizumab (Lucentis; Genentech; South San Francisco, CA) is now widely used as intravitreal anti-VEGF therapy for neovascular AMD. Ranibizumab has a larger molecular weight (149 kDa) than ranibizumab (48 kDa) and its penetration into the retina may be slower than ranibizumab’s. Its clearance from the vitreous may be slower as well, resulting in a longer half-life in the human eye, thus requiring less frequent application. In rabbits, Bakri et al reported a vitreous half-life of 2.88 days after intravitreal injection of 0.5 mg ranibizumab, which indeed is shorter than the half-life reported for bevacizumab (4.32 days) in the same animal model. In monkeys, the vitreous elimination half-life of ranibizumab was determined by Gaudreault et al to be 2.6 days after bilateral intravitreal injection of 0.5 mg of the drug. With the increasing use of intravitreal injections of anti-VEGF substances for various ocular diseases, accurate information on their pharmacokinetics is very important and will help to optimize reinjection intervals and achieve the maximum therapeutic results.

**Disclosure**

No author has a proprietary interest in any of the products mentioned in the article.

**References**


